Metformine Viatris

Metformin, the active ingredient in Metformine Viatris, is a Biguanide presented as an oral tablet for oral use. It reduces hepatic glucose production and enhances peripheral insulin sensitivity, helping to control blood sugar levels in adults with type 2 diabetes mellitus.

GNH USA supplies Metformine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and ensuring reliable global distribution.

Metformine Viatris (metformin) is indicated for conditions within the diabetes treatment pathway.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial glucose levels. - Prediabetes: helps delay progression to overt diabetes when combined with lifestyle measures. - Polycystic ovary syndrome (off‑label): may improve insulin resistance and menstrual regularity.

Metformine Viatris may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea - Diarrhea - Abdominal discomfort - Metallic taste - Loss of appetite - Flatulence

Serious or Rare Side Effects: - Lactic acidosis - Severe hypoglycemia (when combined with other agents) - Hepatotoxicity - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Anemia - Acute renal impairment

Before initiating Metformine Viatris, several safety considerations should be reviewed.

- Renal function: assess eGFR and avoid use in severe impairment. - Hepatic disease: use with caution; monitor liver enzymes. - Cardiac failure: contraindicated in acute decompensated heart failure. - Alcohol intake: limit to reduce risk of lactic acidosis. - Pregnancy and lactation: evaluate risk–benefit; consult healthcare provider. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Metformine Viatris can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of renal dysfunction. - Cimetidine: raises metformin plasma concentrations. - Nucleoside reverse transcriptase inhibitors: elevate lactic acidosis risk. - Alcohol: enhances lactic acidosis potential. - High‑dose diuretics: may affect renal clearance.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - ACE inhibitors/ARBs: monitor renal function. - Sulfonylureas: increased hypoglycemia risk. - Corticosteroids: may raise glucose, requiring dose adjustment. - Thyroid hormones: can alter glucose metabolism.